Stay updated with breaking news from William osai. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GSRGT 2020: Evolution of Systemic Therapies and the Landscape of Clinical Trials Enrolling Patients (UroToday.com) To discuss the evolution of systemic therapies and the landscape of clinical trials among patients with penile cancer, Dr. Philippe Spiess, the co-Course Director of the Global Society of Rare Genitourinary Tumors (GSRGT) 2020 Virtual Summit, invited Dr. Jad Chahoud, his colleague from the Moffitt Cancer Center. Dr. Chahoud started by highlighting that penile cancer is a rare disease in the US, representing 0.7% of all cancer, with high-risk HPV responsible for ~50% of all penile squamous cell carcinoma. The majority of these patients will present with localized or locally advanced disease whereby platinum-based combination chemotherapy remains the front-line therapy. The InPACT trial is actively enrolling patients to determine the frontline therapy for locally advanced penile cancer, given there have been limited treatment advancements in the last decade. ....
GSRGT 2020: The Need for Perioperative Management Strategies: Role of Clinical Oncologists - Chemotherapy (UroToday.com) The penile cancer session at the Global Society of Rare Genitourinary Tumors (GSRGT) 2020 Virtual Summit included a discussion for the role of chemotherapy in the perioperative management of patients with penile cancer by Dr. Guru Sonpavde from the Dana-Farber Cancer Institute. Dr. Sonpavde notes that surgery alone for patients with locally advanced disease is associated with high-risk of recurrence, both locoregionally and distant, with 5-year overall survival (OS) rates of 0-42%. Particularly bad predictors include bulky inguinal adenopathy of ≥ 4cm, bilateral nodes, pelvic lymphadenopathy (N3 disease), an unresectable primary tumor (T4), and extranodal extension. ....